Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
2.
Pediatr Pulmonol ; 56(10): 3349-3357, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34339596

RESUMO

BACKGROUND: Long-term home noninvasive ventilation (NIV) is increasingly employed in children with sleep-disordered breathing and chronic respiratory failure. While studies suggest its successful implementation in tertiary care centers, little is known about the situation in a general care setting. Hence, we aim to evaluate the clinical profiles of these children in a general pediatric unit over the past two decades. METHODS: Data collected retrospectively on patients younger than 18 years old receiving long-term home NIV from January 1, 1997 to December 31, 2017 in a Hong Kong regional general pediatric unit were reviewed. RESULTS: The number of children on home NIV increased more than 10-fold over the past two decades. In total, 114 children were commenced on NIV during the 21-year period. Upper airway obstruction was the most common cause (77%), followed by neuromuscular diseases (16%), pulmonary disorders (4%), and abnormal ventilatory control (3%). Continuous positive airway pressure was the most common NIV type (59%). To date, 46% of the children remained in our NIV program, while 18% discontinued NIV support. NIV adherence increased significantly with follow-up (median of 78.6% and 82.5% at baseline and last follow-up, respectively). Sixty-five percent of the children used NIV for at least 4 h on 70% of the days monitored. Higher body mass index was associated with lower adherence. CONCLUSION: Pediatric home NIV is feasible in the general care setting with good outcomes and adherence. As the demand for NIV service grows, input from local hospitals will be of increasing importance and should be considered upon healthcare planning.


Assuntos
Ventilação não Invasiva , Insuficiência Respiratória , Adolescente , Criança , Pressão Positiva Contínua nas Vias Aéreas , Estudos de Viabilidade , Hong Kong , Humanos , Insuficiência Respiratória/terapia , Estudos Retrospectivos
4.
Sleep Med ; 74: 332-337, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32905994

RESUMO

OBJECTIVE: Heated humidified high flow nasal cannula (HHHFNC) has gained popularity in the treatment of children with respiratory distress and bronchiolitis in the past decade. Its efficacy as a mode of non-invasive respiratory support has been demonstrated in both adults and children. However, reports on its use in the treatment of obstructive sleep apnea (OSA) in infants are limited. We aimed to evaluate the efficacy of HHHFNC therapy as treatment in infants with OSA. METHODS: A retrospective analysis of OSA infants who had undergone polysomnographic titration between 2015 and 2017 was undertaken. Data about the age, gender, AHI, co-morbid conditions and flow used for each patient were retrieved. RESULTS: Ten infants were included in this study (median age 34 weeks; IQR 27-38 weeks). The median optimal HHHFNC flow rate was 8.0 L/min (IQR 6.7-8.0 L/min). HHHFNC significantly reduced median obstructive apnea-hypopnea index (OAHI) from 9.1 (IQR 5.1-19.3) to 0.9 (IQR 0-1.6; P = 0.005) events/h; median obstructive apnea index (OAI) from 5.8 (IQR 1.1-13.4) to 0 (IQR 0-0.9; P = 0.021) events/h; median obstructive hypopnea index (OHI) from 4.1 (IQR 0.9-6.8) to 0.1 (0-0.9; P = 0.017) events/h; and median oxygen saturation (SpO2) nadir increased from 88% (IQR 83-94%) to 94% (IQR 93-96%; P = 0.040). CONCLUSION: HHHFNC significantly reduced respiratory events and improved oxygenation in infants with OSA.


Assuntos
Cânula , Apneia Obstrutiva do Sono , Criança , Temperatura Alta , Humanos , Lactente , Estudos Retrospectivos , Apneia Obstrutiva do Sono/terapia
5.
Vaccine ; 36(24): 3477-3485, 2018 06 07.
Artigo em Inglês | MEDLINE | ID: mdl-29739719

RESUMO

BACKGROUND: Hong Kong has a high burden of influenza hospitalisation. This study estimated influenza vaccine effectiveness in hospitalised Hong Kong children aged 6 months to below 6 years using data potentially obtainable from routine surveillance sources. METHODS: This 'test-negative' case-control study was conducted over two summer and one winter influenza seasons in five public Hong Kong hospitals during 2015 and 2016. Patients admitted for febrile and/or respiratory-associated illnesses who met inclusion criteria were invited to participate. Case-patients were respiratory-associated admissions with nasopharyngeal aspirate or nasopharyngeal swab specimens obtained during the first 48 h of hospitalisation that tested positive for influenza A or B, whereas control-patients were those with specimens that tested negative for both influenza A and B. Reliability of a routinely collected influenza immunisation status form was evaluated. Vaccine effectiveness for administration of full or partial series of influenza vaccination was calculated as 1 minus the odds ratio for influenza vaccination history for case-patients versus control-patients. RESULTS: 2900 eligible subjects had influenza vaccination status available. A simple record form, designed to collect upon admission information on influenza vaccination status, was found to be reliable when compared to confirmed vaccination status from immunisation records and guardians' self-reports. Influenza vaccine effectiveness for preventing influenza A or B hospitalisation in children aged from 6 months to below 6 years during the period June 2015 to November 2016 was 68% (95% confidence interval [CI]: 55%, 77%) from unconditional analyses and 64% (95% CI: 46%, 75%) from conditional analyses. CONCLUSIONS: Seasonal influenza vaccine was effective in preventing hospitalisation from influenza A or B in young Hong Kong children during 2015 and 2016. As influenza vaccination status is not currently routinely recorded, implementation of an influenza immunisation status form in all paediatric wards, and centralising the data in Hong Kong's central computerised database, could provide real-time monitoring of influenza vaccine effectiveness.


Assuntos
Hospitalização/estatística & dados numéricos , Imunogenicidade da Vacina , Vacinas contra Influenza/administração & dosagem , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Vacinação , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Criança , Criança Hospitalizada , Feminino , Hong Kong/epidemiologia , Hospitais , Humanos , Vírus da Influenza A/classificação , Vírus da Influenza A/imunologia , Vírus da Influenza A/isolamento & purificação , Vírus da Influenza B/classificação , Vírus da Influenza B/imunologia , Vírus da Influenza B/isolamento & purificação , Influenza Humana/imunologia , Influenza Humana/virologia , Masculino , Prontuários Médicos , Pessoa de Meia-Idade , Vigilância em Saúde Pública , Estações do Ano
6.
Indian J Pediatr ; 85(8): 658-666, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29308548

RESUMO

Preschool wheeze occurs in half of the children before they reach 6 y of age and recurrence is also common. Recurrent preschool wheeze is classified as either typical or atypical. For typical recurrent preschool wheeze, the diagnoses are either asthma or bronchiolitis/bronchitis. Responsiveness to a properly administered bronchodilator confirms asthma, atopic or otherwise. All atypical preschool wheeze should be referred to pediatric respirologist for assessment. Lung function test by impulse oscillometry (IOS) before and after bronchodilator is helpful to confirm airway hyperresponsiveness, an essential feature of asthma. Assessment of atopy is important by either skin prick test or serum IgE level. Treatment of acute wheeze includes standard supportive care, bronchodilator for those diagnosed with asthma and hypertonic saline for those diagnosed as having acute bronchiolitis. Other treatments included nebulized adrenaline for acute bronchiolitis and systemic steroids for asthma. For those with significant respiratory distress, continuous positive airway pressure (CPAP) or heated humidified high flow should be considered. Daily or intermittent inhaled corticosteroid or intermittent montelukast would reduce asthma exacerbation rate. A significant proportion of preschool wheeze persists till school age. An early diagnosis of asthma would be important to allow early optimal management.


Assuntos
Asma/diagnóstico , Bronquite/diagnóstico , Broncodilatadores/uso terapêutico , Sons Respiratórios , Asma/complicações , Bronquite/complicações , Pré-Escolar , Humanos , Testes de Função Respiratória
7.
J Trop Pediatr ; 64(5): 418-425, 2018 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-29106671

RESUMO

AIM: To evaluate the cost-effectiveness of palivizumab prophylaxis for premature infants born <29 weeks in Hong Kong. METHOD: We evaluated the hospitalization rate for respiratory syncytial virus (RSV) infection within the first 12 months of discharge of a cohort of preterm infants born between 2010 and 2014 at two local hospitals. RESULTS: In total, 40 of 135 infants were given palivizumab. The hospitalization rate for premature infants <29 weeks was reduced from 15.8 to 5% (p = 0.096) and that for infants <27 weeks was reduced from 33.3 to 8.7% (p = 0.046). In the former group, the incremental cost-effectiveness ratio per hospital admission prevented (ICER/HAP) was US dollar (USD) 24 365. In the latter subgroup, the ICER/HAP was USD 3108. CONCLUSION: The cost-effectiveness as measured for infants <27 weeks is more favorable than that for infants <29 weeks.


Assuntos
Anticorpos Monoclonais/economia , Antivirais/farmacologia , Custos de Medicamentos/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Imunoglobulinas Intravenosas/economia , Palivizumab/uso terapêutico , Infecções por Vírus Respiratório Sincicial/economia , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Vírus Sinciciais Respiratórios/imunologia , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Estudos de Coortes , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Feminino , Idade Gestacional , Hong Kong , Hospitalização/economia , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Recém-Nascido , Recém-Nascido Prematuro , Unidades de Terapia Intensiva/estatística & dados numéricos , Tempo de Internação , Palivizumab/economia , Infecções por Vírus Respiratório Sincicial/tratamento farmacológico , Vírus Sinciciais Respiratórios/efeitos dos fármacos , Estações do Ano , Resultado do Tratamento
8.
Complement Ther Med ; 29: 219-228, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27912950

RESUMO

OBJECTIVES: Traditional Chinese medicine are commonly used for treatment of asthma. However, there are only very limited data about its efficacy in children. Therefore, we aimed to determine the efficacy of augmented Yu Ping Feng San (aYPFS) as an add-on to oral montelukast compared with montelukast alone for treatment of mild persistent asthma in children. DESIGN: A single centre, placebo-controlled, double-blinded, randomized control trial was carried out. Participants with age 6-18 years who had mild persistent asthma were randomized according to random number list to receive either aYPFS plus montelukast for 24 weeks or placebo plus montelukast for 24 weeks. Primary outcome measure was lung function parameters. Secondary outcome measures were Asthma Control Test™ (ACT™) and Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores, symptom-free days, short-acting ß2-agonist use, use of rescue oral corticosteroids, days of hospitalization for asthma and number of emergency consultation with GPs or AED department. RESULTS: Twenty-eight participants were randomized to aYPFS group and twenty-nine to placebo group. There was no significant difference in baseline characteristics. There was significant improvement in ACT™ score in aYPFS group (up to 6.9% change from baseline) (p=0.016) but not in the control group. There were no significant differences between groups in other primary and secondary outcome parameters. Dropout because of adverse effects is comparable in both groups. CONCLUSION: Traditional Chinese medicine aYPFS as an add-on to montelukast improved symptoms of asthma control. Further studies with larger sample size are needed to evaluate its efficacy and safety in childhood asthma.


Assuntos
Acetatos/uso terapêutico , Asma/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Quinolinas/uso terapêutico , Adolescente , Criança , Ciclopropanos , Método Duplo-Cego , Feminino , Humanos , Masculino , Medicina Tradicional Chinesa/métodos , Qualidade de Vida , Sulfetos
9.
Pediatr Int ; 49(1): 80-7, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17250511

RESUMO

BACKGROUND: Mercury is a well-known neurotoxin. There are three kinds of mercury exposure: elemental mercury poisoning, inorganic mercury poisoning and organomercury poisoning. Organomercury is the most toxic. Twenty-four hour urine for mercury and blood mercury are the gold standards for diagnosis of mercury poisoning, including low-level chronic mercury exposure. Other tests for mercury level are discussed. The purpose of the present paper was to review recent data on the nature, pathophysiology, pharmacokinetics, diagnostic methods, treatment and the linkage to neurodevelopmental disabilities of mercury exposure in children. METHODS: A literature search was undertaken of MEDLINE (1980-2003), and American Academy of Pediatrics, American Medical Association, American Dental Association, World Health Organization and Center for Disease Control websites. The search string 'mercury' was used in MEDLINE and articles were selected as appropriate by two independent reviewers. All relevant information was reviewed and data were extracted by two independent reviewers. RESULTS: Based on the meta-analysis of the accuracy of hair mercury, hair mercury levels correlated with mercury level in blood (sample size weighted correlation coefficient, r w = 0.61), with 24 h urine ( r w = 0.46) and with cord blood ( r w = 0.64). However, the correlation for hair mercury level with 24 h urine level and blood level was not high enough to replace them in clinical decision-making of individual patient. Epidemiological evidence has shown that low-level mercury poisoning is not a cause of autism (relative risk = 0.49, 95%CI = 0.36-0.66). The risk of neurodevelopmental disabilities from low-level exposure to methylmercury from the regular consumption of fish is still controversial even after combining results from different epidemiological studies worldwide. There is a lack of data in the literature about the effect of chelation therapy in children with neurodevelopmental disabilities. CONCLUSION: Mercury poisoning should be diagnosed only with validated methods. There is no evidence to support the association between mercury poisoning and autism.


Assuntos
Intoxicação por Mercúrio/diagnóstico , Adolescente , Testes Respiratórios , Terapia por Quelação , Criança , Doença Crônica , Exposição Ambiental , Fezes/química , Cabelo/química , Humanos , Mercúrio/análise , Intoxicação por Mercúrio/terapia
10.
Ann Trop Paediatr ; 26(4): 363-6, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17132303

RESUMO

Acute muscle weakness with severe hypokalaemia is not uncommon in adults but is rare in children. An 11-month-old girl presented with hypokalaemic paralysis following a 1-month insufficiency of dietary potassium.


Assuntos
Hipopotassemia/complicações , Debilidade Muscular/etiologia , Deficiência de Potássio/complicações , Doença Aguda , Feminino , Humanos , Lactente , Paralisia/etiologia , Potássio na Dieta/administração & dosagem
11.
Am J Infect Control ; 33(4): 227-9, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15877017

RESUMO

BACKGROUND: Noncontact forehead temperature measurement by handheld infrared thermometer was used as a screening tool for fever. However, the accuracy data and normal range of forehead temperature determined by this method were not available. METHODS: The temperature readings from 3 handheld infrared thermometers were validated against an electronic thermometer. Normal range of forehead temperature was determined by measuring the forehead temperature in 1000 apparently healthy subjects. RESULTS: Significant differences were detected in readings obtained by the 3 different handheld infrared thermometers (analysis of covariance, P < .001) The most accurate one was chosen, and the normal range of forehead temperature in 1000 subjects detected by this method was 31.0 degrees C to 35.6 degrees C. CONCLUSIONS: Our study shows that commercially available, handheld infrared thermometers require individual validation. Forehead temperature in excess of 35.6 degrees C is suggestive of fever. Further studies are required to confirm accuracy of this value in detecting fever.


Assuntos
Temperatura Corporal , Termômetros , Adulto , Feminino , Testa , Humanos , Masculino , Pessoa de Meia-Idade , Valores de Referência
14.
World J Gastroenterol ; 8(4): 703-6, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12174382

RESUMO

AIM: The widespread use of antibacterial therapy has been suggested to be the cause for the decline in the prevalence of Helicobacter pylori infection. This study examine the serial changes of urea breath test results in a group of hospitalized patients who were given antibacterial therapy for non-gastric infections. METHODS: Thirty-five hospitalized patients who were given antibacterial therapy for clinical infections, predominantly chest and urinary infections, were studied. Most (91 %) patients were given single antibiotic of either a penicillin or cephalosporin group. Serial (13)C-urea breath tests were performed within 24 hours of initiation of antibiotics, at one-week and at six-week post-therapy. H. pylori infection was diagnosed when one or more urea breath tests was positive. RESULTS: All 35 patients completed three serial urea breath tests and 26 (74 %) were H. pylori-positive. Ten (38 %) H. pylori-infected patients had at least one negative breath test results during the study period. The medium delta (13)C values were significantly lower at baseline (8.8) than at one-week (20.3) and six-week (24.5) post-treatment in H. pylori-positive individuals (P=0.022). Clearance of H. pylori at six-week was only seen in one patient who had received anti-helicobacter therapy from another source. CONCLUSION: Our results suggested that one-third of H. pylori-infected individuals had transient false-negative urea breath test results during treatment with antibacterial agent. However, clearance of H. pylori infection by regular antibiotic consumption is rare.


Assuntos
Antibacterianos/administração & dosagem , Infecções por Helicobacter/diagnóstico , Ureia/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Testes Respiratórios , Criança , Pré-Escolar , Reações Falso-Negativas , Feminino , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Humanos , Masculino , Pessoa de Meia-Idade
15.
Int J Pediatr Otorhinolaryngol ; 62(3): 257-60, 2002 Feb 25.
Artigo em Inglês | MEDLINE | ID: mdl-11852131

RESUMO

Pharyngitis is a common condition and usually does not lead to any major complication. We report a case in which the patient presented with pharyngitis resulting in an unusual fatal complication of pharyngeal and cerebral abscess. The causative organism was Streptococcus milleri that should be readily treatable by penicillin if the condition was recognised earlier.


Assuntos
Abscesso Encefálico/etiologia , Faringite/complicações , Abscesso Retrofaríngeo/etiologia , Infecções Estreptocócicas/complicações , Adolescente , Abscesso Encefálico/diagnóstico , Erros de Diagnóstico , Evolução Fatal , Feminino , Humanos , Deficiência Intelectual , Faringite/microbiologia , Abscesso Retrofaríngeo/diagnóstico , Infecções Estreptocócicas/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...